ProjectSIMPLIFY – A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg…
Basic data
Acronym:
SIMPLIFY
Title:
A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis
Duration:
01/01/2016 to 01/01/2016
Abstract / short description:
A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis
Keywords:
multiple sclerosis
Multiple Sklerose
Involved staff
Managers
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Diagnostic and Interventional Neuroradiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Maidenhead, United Kingdom